Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Empagliflozin on Cardiac Microvasculature in Type 2 Diabetes
NCT04203927Phase 1Unknown
- Sponsor
- University of Virginia
- Start
- Feb 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Myocardial microvascular perfusion at 12 weeks. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04203927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203927.